PortalPublikationenPrimary intracranial soft tissue sarcoma in children and ado...

Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups

Standard

Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups. / Benesch, Martin; von Bueren, André O; Dantonello, Tobias; von Hoff, Katja; Pietsch, Torsten; Leuschner, Ivo; Claviez, Alexander; Bierbach, Uta; Kropshofer, Gabriele; Korinthenberg, Rudolf; Graf, Norbert; Suttorp, Meinolf; Kortmann, Rolf Dieter; Friedrich, Carsten; von der Weid, Nicolas; Kaatsch, Peter; Klingebiel, Thomas; Koscielniak, Ewa; Rutkowski, Stefan.

in: J NEURO-ONCOL, Jahrgang 111, Nr. 3, 3, 2013, S. 337-345.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Benesch, M, von Bueren, AO, Dantonello, T, von Hoff, K, Pietsch, T, Leuschner, I, Claviez, A, Bierbach, U, Kropshofer, G, Korinthenberg, R, Graf, N, Suttorp, M, Kortmann, RD, Friedrich, C, von der Weid, N, Kaatsch, P, Klingebiel, T, Koscielniak, E & Rutkowski, S 2013, 'Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups', J NEURO-ONCOL, Jg. 111, Nr. 3, 3, S. 337-345. https://doi.org/10.1007/s11060-012-1020-3

APA

Benesch, M., von Bueren, A. O., Dantonello, T., von Hoff, K., Pietsch, T., Leuschner, I., Claviez, A., Bierbach, U., Kropshofer, G., Korinthenberg, R., Graf, N., Suttorp, M., Kortmann, R. D., Friedrich, C., von der Weid, N., Kaatsch, P., Klingebiel, T., Koscielniak, E., & Rutkowski, S. (2013). Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups. J NEURO-ONCOL, 111(3), 337-345. [3]. https://doi.org/10.1007/s11060-012-1020-3

Vancouver

Benesch M, von Bueren AO, Dantonello T, von Hoff K, Pietsch T, Leuschner I et al. Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups. J NEURO-ONCOL. 2013;111(3):337-345. 3. https://doi.org/10.1007/s11060-012-1020-3

Bibtex

@article{93405f2f52584eef9e7e47df92a5a905,
title = "Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups",
abstract = "Purely intracranial soft tissue sarcomas (ISTS) are very rare among children. A retrospective database analysis of the Cooperative Weichteilsarkom Studiengruppe (CWS) and brain tumor (HIT) registries was conducted to describe treatment and long-term outcome of children and adolescents with ISTS. Nineteen patients from Germany, Austria and Switzerland were reported between 1988 and 2009. Median age at diagnosis was 9.7 years (range, 0.5-17.8). Central pathological review was performed in 17 patients. Eleven patients underwent a total and five a subtotal tumor resection. A biopsy was done in one patient. In two patients no data concerning extent of initial resection was available. Radiotherapy was performed in 15 patients (first-line, n = 11; following progression, n = 4). All but one patient received chemotherapy (first-line, n = 7, following progression, n = 5; first-line and following progression, n = 6). With a median follow-up of 5.8 years (range, 0.6-19.8) ten patients were alive in either first or second complete remission. Seven patients died due to relapse or progression and two were alive with progressive disease. Estimated progression-free and overall survival at 5 years were 47 % (±12 %) and 74 % (±10 %), respectively. About 50 % of patients with ISTS remain relapse-free after 5 years. Multimodality treatment including complete tumor resection and radio-/chemotherapy is required to achieve sustained tumor control in patients with ISTS. Early initiation of postoperative non-surgical treatment seems to be important to prevent recurrence. Due to the intracranial localization local therapy should follow the recommendations used in brain tumors rather than in soft tissue sarcomas, whereas chemotherapy should be guided by histological subtype.",
author = "Martin Benesch and {von Bueren}, {Andr{\'e} O} and Tobias Dantonello and {von Hoff}, Katja and Torsten Pietsch and Ivo Leuschner and Alexander Claviez and Uta Bierbach and Gabriele Kropshofer and Rudolf Korinthenberg and Norbert Graf and Meinolf Suttorp and Kortmann, {Rolf Dieter} and Carsten Friedrich and {von der Weid}, Nicolas and Peter Kaatsch and Thomas Klingebiel and Ewa Koscielniak and Stefan Rutkowski",
year = "2013",
doi = "10.1007/s11060-012-1020-3",
language = "English",
volume = "111",
pages = "337--345",
journal = "J NEURO-ONCOL",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

RIS

TY - JOUR

T1 - Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups

AU - Benesch, Martin

AU - von Bueren, André O

AU - Dantonello, Tobias

AU - von Hoff, Katja

AU - Pietsch, Torsten

AU - Leuschner, Ivo

AU - Claviez, Alexander

AU - Bierbach, Uta

AU - Kropshofer, Gabriele

AU - Korinthenberg, Rudolf

AU - Graf, Norbert

AU - Suttorp, Meinolf

AU - Kortmann, Rolf Dieter

AU - Friedrich, Carsten

AU - von der Weid, Nicolas

AU - Kaatsch, Peter

AU - Klingebiel, Thomas

AU - Koscielniak, Ewa

AU - Rutkowski, Stefan

PY - 2013

Y1 - 2013

N2 - Purely intracranial soft tissue sarcomas (ISTS) are very rare among children. A retrospective database analysis of the Cooperative Weichteilsarkom Studiengruppe (CWS) and brain tumor (HIT) registries was conducted to describe treatment and long-term outcome of children and adolescents with ISTS. Nineteen patients from Germany, Austria and Switzerland were reported between 1988 and 2009. Median age at diagnosis was 9.7 years (range, 0.5-17.8). Central pathological review was performed in 17 patients. Eleven patients underwent a total and five a subtotal tumor resection. A biopsy was done in one patient. In two patients no data concerning extent of initial resection was available. Radiotherapy was performed in 15 patients (first-line, n = 11; following progression, n = 4). All but one patient received chemotherapy (first-line, n = 7, following progression, n = 5; first-line and following progression, n = 6). With a median follow-up of 5.8 years (range, 0.6-19.8) ten patients were alive in either first or second complete remission. Seven patients died due to relapse or progression and two were alive with progressive disease. Estimated progression-free and overall survival at 5 years were 47 % (±12 %) and 74 % (±10 %), respectively. About 50 % of patients with ISTS remain relapse-free after 5 years. Multimodality treatment including complete tumor resection and radio-/chemotherapy is required to achieve sustained tumor control in patients with ISTS. Early initiation of postoperative non-surgical treatment seems to be important to prevent recurrence. Due to the intracranial localization local therapy should follow the recommendations used in brain tumors rather than in soft tissue sarcomas, whereas chemotherapy should be guided by histological subtype.

AB - Purely intracranial soft tissue sarcomas (ISTS) are very rare among children. A retrospective database analysis of the Cooperative Weichteilsarkom Studiengruppe (CWS) and brain tumor (HIT) registries was conducted to describe treatment and long-term outcome of children and adolescents with ISTS. Nineteen patients from Germany, Austria and Switzerland were reported between 1988 and 2009. Median age at diagnosis was 9.7 years (range, 0.5-17.8). Central pathological review was performed in 17 patients. Eleven patients underwent a total and five a subtotal tumor resection. A biopsy was done in one patient. In two patients no data concerning extent of initial resection was available. Radiotherapy was performed in 15 patients (first-line, n = 11; following progression, n = 4). All but one patient received chemotherapy (first-line, n = 7, following progression, n = 5; first-line and following progression, n = 6). With a median follow-up of 5.8 years (range, 0.6-19.8) ten patients were alive in either first or second complete remission. Seven patients died due to relapse or progression and two were alive with progressive disease. Estimated progression-free and overall survival at 5 years were 47 % (±12 %) and 74 % (±10 %), respectively. About 50 % of patients with ISTS remain relapse-free after 5 years. Multimodality treatment including complete tumor resection and radio-/chemotherapy is required to achieve sustained tumor control in patients with ISTS. Early initiation of postoperative non-surgical treatment seems to be important to prevent recurrence. Due to the intracranial localization local therapy should follow the recommendations used in brain tumors rather than in soft tissue sarcomas, whereas chemotherapy should be guided by histological subtype.

U2 - 10.1007/s11060-012-1020-3

DO - 10.1007/s11060-012-1020-3

M3 - SCORING: Journal article

C2 - 23229762

VL - 111

SP - 337

EP - 345

JO - J NEURO-ONCOL

JF - J NEURO-ONCOL

SN - 0167-594X

IS - 3

M1 - 3

ER -